Fair point, although if you follow your own “leave it all to the...

Fair point, although if you follow your own “leave it all to the experts running the show” advice, you (or anyone for that matter) shouldn’t need to post in here about the P2b trial until trial completion and read-out next year.

We know that’s not gonna happen.

None of us here in discussion (imo) have the hubris to think that anything we say is going to affect company strategy (or the stock price - unlike yourself). It’s a way of testing and expressing ideas, gaining knowledge, validating correct assumptions, and correcting false ones, as we aren’t experts (but we are part owners of the company).

Just speaking for myself, some posts (and posters in general) are extremely helpful to myself in righting the knowledge ship.

I’ve learned a lot about one of our chief competitors for instance, information that I wouldn’t have got easily, or at all, from corporate press releases or 300+ pages of trial results, Thanks Dalts, Sam, Chilunsin, and meph.

However, I perhaps suffer from the hubris that my thoughts are worth a post that merits others’ reading it.

Apologies to those who are unable to give a thumbs down.